Britain and America have finalized a landmark trade agreement that will ensure no duties on UK drug shipments going into the US market.
Agreement Details of the Deal
As part of the deal, the UK has committed to boost funding on drugs through the NHS. This pledge guarantees that duties on these key products will remain at nothing for a duration of 36 months.
This development comes after recent warnings to dramatically increase import taxes on patented drug products, with potential rates floated up to one hundred percent.
"This deal between the UK bolsters the international landscape for cutting-edge drugs and establishes much-needed equity to American-British drug exports," a release noted.
Trade Significance
Medicines are one of the UK's biggest goods shipped to the United States, which is by far the biggest buyer for major companies like GSK and AstraZeneca.
Trade data reveal that in the one-year period leading up to last September, the UK exported medicines totaling over eleven billion pounds to the US. This figure made up nearly one-fifth of British export trade in that timeframe.
"This guarantee protects jobs, boosts capital expenditure and sets the stage for the UK to establish itself as a international leader for life sciences," a government official stated.
Detailed UK Commitments
The deal entails several key changes from the British government:
- Revised Affordability Limit: The UK will lift the price threshold at which it judges new medicines to be unaffordable by 25%.
- Higher Drug Budget: There is a goal to increase total public funding on medicines from 0.3 percent of GDP to 0.6% over the next decade.
- Rebate Cap: The amount drug companies must pay back to the NHS to control costs will be capped at fifteen percent. Previously, rebates were more than twenty percent.
Recent Tensions
The pact comes amid a long-running tension between the sector and the UK government over spending levels and regulatory access.
This friction were intensified by assertions that US consumers were paying a premium for the same drugs than consumers in the UK and Europe.
In recent months, several large manufacturing plans in the UK have been halted or abandoned, while multi-billion-dollar expansions have been directed toward US facilities.
The Science Minister acknowledged that the NHS needed to increase expenditure on treatments, noting that its expenditure on drugs had decreased as a percentage of its overall budget over the last ten years.
